CHF Solutions

Nuwellis, Inc. operates as a medical device company. It engages in the provision of products for the treatment of fluid overload. The firm's products include Aquadex FlexFlow System, which provides an ultrafiltration for the removal of salt and water in patients with hypervolemia, or fluid overload. It operates through Cardiac and Coronary Disease Products segment. The company was founded by Crispin Marsh and William S. Peters in November 1999 and is headquartered in Eden Prairie, MN.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

EDEN PRAIRIE, Minn., Sept.  23, 2020  (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to improving the lives of patients suffering from fluid overload conditions, today announced it will be providing testimony to the U.S. International Trade Commission (USITC) concerning the availability of U.S.-sourced medical supplies to treat COVID-19 and future pandemics.

CHF Solutions to Share COVID-19 Experience with Leading Government Commission

EDEN PRAIRIE, Minn., Sept.  11, 2020  (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to changing the lives of patients suffering from fluid overload, today announced the company will participate in Lake Street Capital Markets’ 4th Annual Best Ideas Growth Conference, being held virtually.  Nestor Jaramillo, President and Chief Operating Officer, and Claudia Drayton, Chief Financial Officer, will be holding one-on-one meetings with investors on Thursday, September 17, 2020.

CHF Solutions to Participate at Lake Street Capital Markets’ 4th Annual BIG4 Conference on September 17, 2020

EDEN PRAIRIE, Minn., Sept.  10, 2020  (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to changing the lives of patients suffering from fluid overload, today announced key takeaways from a recent webinar, where Dr. John L. Jefferies discussed the use of precision medicine for the treatment of fluid overload in heart failure (HF) patients, including alternatives to diuretics, such as ultrafiltration using the Aquadex SmartFlow™ system.

CHF Solutions’ Physician-Led Webinar Concludes Fluid Overloaded Heart Failure Patients Benefit from Ultrafiltration

EDEN PRAIRIE, Minn., Sept.  01, 2020  (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to changing the lives of patients suffering from fluid overload, announced today receipt of written notification from the Nasdaq Stock Market that it has granted the company’s request for an 180-day extension to regain compliance with Nasdaq’s minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). The company now has until February 24, 2021 to meet the requirement.

CHF Solutions Receives 180-Day Extension to Meet Nasdaq Minimum Bid Price Requirement

EDEN PRAIRIE, Minn., Aug.  27, 2020  (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to improving the lives of patients suffering from fluid overload, today commended a request from the U.S. Congress to the U.S. International Trade Commission (USITC) concerning the availability of U.S.-sourced medical supplies to treat COVID-19 and future pandemics.

CHF Solutions Applauds U.S Congress Request to U.S. International Trade Commission to Identify Products to Treat COVID-19

EDEN PRAIRIE, Minn., Aug.  21, 2020  (GLOBE NEWSWIRE) -- CHF Solutions, Inc. (NASDAQ:CHFS) today announced the closing of an underwritten public offering of units for gross proceeds of approximately $14.37 million, which includes the full exercise of the underwriter's over-allotment option to purchase additional shares and warrants, prior to deducting underwriting discounts and commissions and offering expenses payable by CHF Solutions.

CHF Solutions, Inc. Announces Closing of $14.37 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option

EDEN PRAIRIE, Minn., Aug.  19, 2020  (GLOBE NEWSWIRE) -- CHF Solutions, Inc. (NASDAQ:CHFS), a medical device company dedicated to improving the lives of patients suffering from fluid overload, today announced the pricing of an underwritten public offering of units for gross proceeds of approximately $12.5 million prior to deducting underwriting discounts and commissions and offering expenses payable by CHF Solutions. The offering is comprised of 27,774,195 Units, priced at a public offering price of $0.45 per unit, with each unit consisting of one share of common stock and a warrant to purchase one share of common stock at an exercise price of $0.45 per share that expires on the fifth anniversary of the date of issuance.

CHF Solutions, Inc. Announces Pricing of $12.5 Million Underwritten Public Offering

EDEN PRAIRIE, Minn., Aug.  18, 2020  (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to improving the lives of patients suffering from fluid overload, today announced that its Aquadex™ product line has been added to the Federal Supply Schedule, expanding access to all federal government agencies, including the Department of Veterans Affairs (VA), Indian Health Services (IHS) and Department of Defense (DOD) Medical Treatment Facilities.

CHF Solutions’ Aquadex Products Granted Federal Supply Schedule Contract

CHF Solutions, Inc. (CHFS) CEO John Erb on Q2 2020 Results - Earnings Call Transcript

EDEN PRAIRIE, Minn., Aug.  04, 2020  (GLOBE NEWSWIRE) -- CHF Solutions, Inc. (Nasdaq: CHFS) announced today its results for the second quarter ended June 30, 2020, which included the following highlights:

CHF Solutions, Inc. Announces 14 Percent Increase in Revenue for Second Quarter 2020 Over Previous Quarter and Provides Company Update

EDEN PRAIRIE, Minn., July  30, 2020  (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq: CHFS) today announced the signing of a distribution agreement with SysteMedic Ltd., covering Israel and Palestine, representing the second distribution partnership in the Middle East region.  Ultrafiltration therapy is now available in 16 countries outside the U.S.

CHF Solutions Further Expands Commercial Presence in the Middle East with Distribution Arrangement for Israel and Palestine

EDEN PRAIRIE, Minn., July  28, 2020  (GLOBE NEWSWIRE) -- CHF Solutions, Inc. (NASDAQ: CHFS) announces today that its second quarter 2020 financial results will be released on Tuesday, August 4, 2020. The company will host a conference call and webcast at 9:00 AM ET that morning, during which management will discuss the company's financial results and provide a general business overview.

CHF Solutions, Inc. To Announce Second Quarter 2020 Financial Results on August 4, 2020

EDEN PRAIRIE, Minn., July  16, 2020  (GLOBE NEWSWIRE) --  CHF Solutions  (Nasdaq: CHFS), a medical device company dedicated to improving the lives of patients suffering from fluid overload, today announced the development of a pediatric registry through a partnership with the Acute Kidney Injury Critical Care Research Foundation and Watermark Research Partners. The registry will collect real-world evidence on the use of the Aquadex SmartFlow™ ultrafiltration system in pediatric patients with fluid overload.

CHF Solutions Announces Registry for Fluid Overload Conditions in Pediatric Patients

EDEN PRAIRIE, Minn., July  14, 2020  (GLOBE NEWSWIRE) --  CHF Solutions  (Nasdaq: CHFS), a medical device company dedicated to improving the lives of patients suffering from fluid overload, today announced key takeaways from a recent webinar where David Askenazi, M.D. MSPH shared his experience and perspectives on the treatment of fluid overload in pediatric patients weighing more than 20 kg.

CHF Solutions Continues Physician-Led Webinar Series with Focus on Treatment of Fluid Overload in Pediatric Patients

EDEN PRAIRIE, Minn., July  08, 2020  (GLOBE NEWSWIRE) --  CHF Solutions  (Nasdaq: CHFS) and  RenalSense, Ltd. , today announced the signing of a distribution agreement to offer complementary solutions for fluid management. The agreement allows CHF Solutions to market and sell RenalSense’s Clarity RMS™ (real-time monitoring system) in certain U.S. territories.  Clarity RMS is a critical care monitoring system that continuously measures urine flow rates and automatically transmits real-time data and fluctuation notifications to medical staff on a 24/7 basis. This information reflects changes in renal function and provides an early sign of acute kidney injury (AKI) risk, enabling rapid intervention with therapeutic solutions such as CHF Solutions’ Aquadex SmartFlow™ ultrafiltration system.

CHF Solutions and RenalSense Enter Distribution Partnership to Offer Ultrafiltration and Real-Time Renal Diagnostics

EDEN PRAIRIE, Minn., June  25, 2020  (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to improving the lives of patients suffering from fluid overload, today announced the promotion of Nestor Jaramillo, Jr. to President and Chief Operating Officer, effective July 1, 2020. In his expanded role, Mr. Jaramillo now will have responsibility for Operations, Engineering, Product Development, Regulatory, Quality, Clinical Affairs, Reimbursement and Human Resources, in addition to the Commercial functions.

CHF Solutions Promotes Nestor Jaramillo, Jr. to President and Chief Operating Officer

EDEN PRAIRIE, Minn., June  18, 2020  (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to improving the lives of patients suffering from fluid overload, announces key conclusions from yesterday’s webinar during which experts in fluid management and critical care provided their perspectives. The webinar highlighted the recent publication: SARS-CoV-2 (COVID-19) and intravascular volume management strategies in the critically ill.1 and the role of ultrafiltration in the treatment of patients with COVID-19.

Clinical Experts Discuss Fluid Management Strategies in Critically Ill COVID-19 Patients during CHF Solutions Webinar

Renowned physicians to offer perspectives from the front lines in Italy and the United States Renowned physicians to offer perspectives from the front lines in Italy and the United States

CHF Solutions to Host Webinar Discussing Fluid Management Strategies in Critically Ill COVID-19 Patients

EDEN PRAIRIE, Minn., June  11, 2020  (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to changing the lives of patients suffering from fluid overload, today announced that it has sold Aquadex SmartFlow™ consoles and disposables to a critical care hospital for use in the treatment of COVID-19 patients in Central Florida.

CHF Solutions Ships Aquadex SmartFlow Products to Florida for Use with COVID-19 Patients

EDEN PRAIRIE, Minn., June  04, 2020  (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq: CHFS) today announced Children’s Hospital of The King’s Daughters (CHKD) in Norfolk, Virginia has initiated ultrafiltration therapy using the Aquadex SmartFlow™ system.

CHF Solutions Announces the Launch of Pediatric Ultrafiltration Therapy Using the Aquadex SmartFlow System at Children’s Hospital of The King’s Daughters

CHF Solutions, Inc. Announces Adjournment of Annual Meeting of Stockholders

EDEN PRAIRIE, Minn., May  20, 2020  (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to changing the lives of patients suffering from fluid overload, today announced a publication highlighting the use of ultrafiltration for fluid management of critically ill patients suffering from COVID-19. “SARS-CoV-2 (COVID-19) and Intravascular Volume Management Strategies in the Critically Ill”1 calls attention to fluid stewardship in COVID-19 patients by judiciously applying the evidence-based resuscitation principles to the specific clinical features of COVID-19 patients.

Publication Highlights Use of Ultrafiltration for Fluid Management in COVID-19 Patients

CHF Solutions (CHFS) CEO, John Erb on Q1 2020 Results - Earnings Call Transcript

Shares of CHF Solutions (NASDAQ:CHFS) rose by 5% in pre-market trading after the company reported Q1 results.

Recap: CHF Solutions Q1 Earnings

EDEN PRAIRIE, Minn., May  12, 2020  (GLOBE NEWSWIRE) -- CHF Solutions, Inc. (Nasdaq: CHFS) announced today its results for the first quarter ended March 31, 2020, which included the following highlights:

News for CHF Solutions Stock (CHFS)